<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2021.8093</article-id>
<article-id pub-id-type="publisher-id">OR-0-0-8093</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>circNSUN2 promotes the malignant biological behavior of colorectal cancer cells via the miR-181a-5p/ROCK2 axis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Chi</surname><given-names>Junlin</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref>
<xref rid="fn1-or-0-0-8093" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shuang</given-names></name>
<xref rid="af2-or-0-0-8093" ref-type="aff">2</xref>
<xref rid="fn1-or-0-0-8093" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Wu</surname><given-names>Zhizhong</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref>
<xref rid="fn1-or-0-0-8093" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yanqiang</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Shi</surname><given-names>Chengmin</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Tong</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Binghong</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Yujian</given-names></name>
<xref rid="af1-or-0-0-8093" ref-type="aff">1</xref>
<xref rid="c1-or-0-0-8093" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Dong</surname><given-names>Xiangqian</given-names></name>
<xref rid="af3-or-0-0-8093" ref-type="aff">3</xref>
<xref rid="c2-or-0-0-8093" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-or-0-0-8093"><label>1</label>Department of Gastrointestinal Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China</aff>
<aff id="af2-or-0-0-8093"><label>2</label>Department of Ultrasound, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China</aff>
<aff id="af3-or-0-0-8093"><label>3</label>Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China</aff>
<author-notes>
<corresp id="c1-or-0-0-8093"><italic>Correspondence to</italic>: Dr Yujian Zeng, Department of Gastrointestinal Surgery, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Wuhua, Kunming, Yunnan 650032, P.R. China, E-mail: <email>zeng_yujian@yeah.com</email></corresp>
<corresp id="c2-or-0-0-8093">Dr Xiangqian Dong, Department of Gastroenterology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Wuhua, Kunming, Yunnan 650032, P.R. China, E-mail: <email>dongxiangqian86@163.com</email></corresp>
<fn id="fn1-or-0-0-8093"><label>&#x002A;</label><p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>07</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>05</month>
<year>2021</year></pub-date>
<volume>46</volume>
<issue>1</issue>
<elocation-id>142</elocation-id>
<history>
<date date-type="received"><day>27</day><month>04</month><year>2020</year></date>
<date date-type="accepted"><day>24</day><month>09</month><year>2020</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Chi et al.</copyright-statement>
<copyright-year>2021</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Aberrant expression of circular RNAs (circRNAs) has been demonstrated to be related to the development of colorectal cancer (CRC), the third most common cancer worldwide. However, the mechanism of the effect of circRNA NOP2/Sun domain family, member 2 (circNSUN2) on the malignant biological behavior of CRC remains unclear. In the present study, the expression of circNSUN2 and microRNA (miR)-181a-5p was detected by RT-qPCR. The expression of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) was measured by western blotting. Cell proliferation was detected by CCK-8 assay. The cell apoptosis rate was measured by flow cytometry. Cell migration ability was evaluated by Transwell assay. The interactions between circNSUN2, miR-181a-5p and ROCK2 were verified by dual-luciferase reporter assay. The results revealed that circNSUN2 was highly expressed in CRC tissues and cell lines. Knockdown of circNSUN2 inhibited the malignant biological behavior of CRC <italic>in vivo</italic> and <italic>in vitro</italic>. Moreover, miR-181a-5p was revealed to be a target gene of circNSUN2, and the expression of ROCK2 was negatively regulated by miR-181a-5p. Knockdown of circNSUN2 inhibited proliferation and migration, and induced apoptosis of CRC cells and suppressed tumor growth by targeting miR-181a-5p to decrease ROCK2 expression. In conclusion, circNSUN2 promoted the progression of CRC by sponging miR-181a-5p to increase the expression of ROCK2.</p>
</abstract>
<kwd-group>
<kwd>circRNA NOP2/Sun domain family</kwd>
<kwd>member 2</kwd>
<kwd>microRNA-181a-5p</kwd>
<kwd>Rho-associated coiled-coil-containing protein kinase 2</kwd>
<kwd>proliferation</kwd>
<kwd>apoptosis</kwd>
<kwd>migration</kwd>
<kwd>colorectal cancer</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University</funding-source>
<award-id>2019FE001(&#x2212;039)</award-id>
<award-id>2019FE001(&#x2212;302)</award-id>
</award-group>
<award-group>
<funding-source>Leader Training Program in Medical Subjects of Health and Family Planning Commission of Yunnan Province</funding-source>
<award-id>D-201657</award-id>
</award-group>
<award-group>
<funding-source>Department of Science and Technology of Yunnan Province</funding-source>
<award-id>201801YH00021</award-id>
</award-group>
<funding-statement>The present study was supported by the Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University [grant nos. 2019FE001(&#x2212;039)] and [2019FE001(&#x2212;302)]. It was also supported by the Leader Training Program in Medical Subjects of Health and Family Planning Commission of Yunnan Province (grant no. D-201657) and by the Department of Science and Technology of Yunnan Province (grant no. 201801YH00021).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Colorectal cancer (CRC) is the third most common cancer worldwide (<xref rid="b1-or-0-0-8093" ref-type="bibr">1</xref>), and with changes in diet and lifestyle, the incidence of CRC is continuously increasing (<xref rid="b2-or-0-0-8093" ref-type="bibr">2</xref>). The risk of CRC is due to increased migration and invasion of CRC cells. The high migration and invasion of CRC cells promotes the progression of CRC (<xref rid="b3-or-0-0-8093" ref-type="bibr">3</xref>,<xref rid="b4-or-0-0-8093" ref-type="bibr">4</xref>). In addition, the high migration and invasion of CRC cells also leads to poor prognosis of CRC patients after surgical resection (<xref rid="b5-or-0-0-8093" ref-type="bibr">5</xref>). Therefore, it is necessary to find effective targets for CRC.</p>
<p>Circular RNAs (circRNAs) are a class of noncoding RNAs that have been revealed to be involved in numerous human diseases including cancer (<xref rid="b6-or-0-0-8093" ref-type="bibr">6</xref>,<xref rid="b7-or-0-0-8093" ref-type="bibr">7</xref>). Recent studies have indicated that circRNAs play vital roles in cancer development and may serve as novel therapeutic targets for cancer (<xref rid="b8-or-0-0-8093" ref-type="bibr">8</xref>&#x2013;<xref rid="b10-or-0-0-8093" ref-type="bibr">10</xref>). In the present study, the function of circRNA NOP2/Sun domain family, member 2 (circNSUN2) and underlying mechanisms in the development of CRC were examined.</p>
<p>It has been reported that circRNAs function as microRNA (miRNA) sponges to regulate the expression of target mRNAs. For example, it has been revealed that miR-3187-3p, as a sponge of circ-ITGA7, regulated ASXL1 by inhibiting the proliferation of CRC (<xref rid="b11-or-0-0-8093" ref-type="bibr">11</xref>). Huang <italic>et al</italic> (<xref rid="b10-or-0-0-8093" ref-type="bibr">10</xref>) demonstrated that circAKT3 activated PIK3R1 via downregulation of miR-198 and enhanced cisplatin in gastric cancer. miR-181a-5p, which is involved in the development of cancer, has been widely reported. A previous study revealed that miR-181a-5p, as a sponge of circ-0068871, regulated the progression of bladder cancer (<xref rid="b12-or-0-0-8093" ref-type="bibr">12</xref>). Notably, the aberrant expression of miR-181a-5p in CRC has also been reported (<xref rid="b13-or-0-0-8093" ref-type="bibr">13</xref>). Moreover, based on bioinformatics data, miR-181a-5p has been revealed to be one of the target genes of circNSUN2. In addition, Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), an effector of the small GTPase Rho, has been identified as a target of miR-181a-5p. ROCK2 has been revealed as a key element in cancer growth and progression (<xref rid="b14-or-0-0-8093" ref-type="bibr">14</xref>,<xref rid="b15-or-0-0-8093" ref-type="bibr">15</xref>). However, to the best of our knowledge, there have been no studies concerning the effect of the circNSUN2/miR-181a-5p/ROCK2 axis on the development of CRC.</p>
<p>In the present study, the expression levels of circNSUN2, miR-181a-5p and ROCK2 in CRC were detected, and the relationship between circNSUN2, miR-181a-5p and ROCK2 was verified. Furthermore, the underlying mechanism of the effect of circNSUN2 on the malignant biological behavior of CRC was demonstrated. The present study thus suggests a previously unknown role of circNSUN2 in CRC and provides the mechanism of circNSUN2 in malignant biological behavior of CRC.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Tissue samples</title>
<p>Human colorectal cancer tissues and adjacent tissues were collected from 32 patients at the First Affiliated Hospital of Kunming Medical University between December 2018 and June 2019. These patients included 18 males and 14 females. The age range of patients was 20&#x2013;60 years old with an average age of 40.57&#x00B1;11.24 years. The present study was approved by the Ethics Committee of First Affiliated Hospital of Kunming Medical University (Ethical approval no. 2018-L-41) and all patients provided informed consent.</p>
</sec>
<sec>
<title>Cell culture</title>
<p>The human normal colonic epithelial cell line NCM460 (item no. MJ-550) was purchased from Shanghai Mingjing Biotechnology Co., Ltd. The colorectal cancer cell line HCT116 (item no. C4111) was purchased from Shanghai Guandao Biotechnology Co., Ltd. The colorectal cancer cell line DiFi (BSC-5023479758-01) was purchased from Shanghai Binsui Biotechnology Co., Ltd. The colorectal cancer cell line HROC18 (product no. CE18870) was purchased from Beijing Crisprbio Biotechnology Co., Ltd. The colorectal cancer cell line T84 (product no. YB-H3024) was purchased from Shanghai Yubo Biotechnology Co., Ltd. 293T cells (cell bank no. KCB200744Y) were obtained from the Chinese Academy of Sciences. Cells were cultured in RPMI-1640 culture medium (product code 0050001DJ; Invitrogen; Thermo Fisher Scientific, Inc.) with 10&#x0025; fetal calf serum (item no. 21097; Cayman Chemical Company), 100 U/ml penicillin and streptomycin (product code DXT-11074440001; Roche Diagnostics). Cells were maintained at 37&#x00B0;C and 5&#x0025; CO<sub>2</sub>.</p>
</sec>
<sec>
<title>Cell transfection</title>
<p>Small interfering (si)-circNSUN2 (5&#x2032;-AUCAUAAGGUAUCCUGAAGAACUUG-3&#x2032;), and circNSUN2 si-negative control (NC) (5&#x2032;-UUCUCCGAACGUGUCACGUTT-3&#x2032;), miR-181a-5p inhibitor (5&#x2032;-ACUCACCGACAGCGUUGAAUGUU-3&#x2032;), and miR-181a-5p inhibitor NC (5&#x2032;-CAGUACUUUUGUGUAGUACAA-3&#x2032;), si-ROCK2 (5&#x2032;-GGATAAACATGGACATCTA-3&#x2032;) and si-con (5&#x2032;-CAGUACUUUUGUGUAGUACAA-3&#x2032;), miR-181a-5p mimic (5&#x2032;-AACAUUCAACGCUGUCGGUGAGU-3&#x2032;) and miR-181a-5p NC mimics (5&#x2032;-UUUGUACUACACAAAAGUACUG-3&#x2032;) were constructed by Guangzhou RiboBio Biotechnology Co., Ltd. The HCT116 and T84 cells (2&#x00D7;10<sup>5</sup>) were seeded in a 6-well plate, and NC (50 nM), si-circNSUN2 (50 nM), NC mimics (50 nM), miR-181a-5p mimics (50 nM), miR-181a-5p inhibitor (100 nM), si-con (100 nM) and si-ROCK2 (100 nM), were transfected by Lipofectamine 2000 transfection reagent (item no. J44705; Duoxi) at 37&#x00B0;C for 24 h according to the manufacturer&#x0027;s protocol.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative (RT-q) PCR</title>
<p>RT-qPCR was used to examine the expression of circNSUN2 and miR-181a-5p. TRIzol reagent (cat. no. 15596018; Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract tissue and cell RNA. The total RNA (1 &#x00B5;g) was used as template for cDNA synthesis using SuperScript III Reverse Transcriptase (cat. no. 18080093; Invitrogen; Thermo Fisher Scientific, Inc.). The tissue and HCT116 or T84 cell cDNA was diluted for PCR amplification using SYBR Green PCR Master Mix (product code SR1110; Solarbio Life Sciences). RT-qPCR was performed at 95&#x00B0;C for 1 min, 40 cycles at 95&#x00B0;C for 10 sec and 58&#x00B0;C for 40 sec. The following primer sequences were used: circNSUN2 forward, 5&#x2032;-GGAUACCUUAUGAUGAGGCCGC-3&#x2032; and reverse, 5&#x2032;-UGAGGAGCAGUGGUGGGAUC-3&#x2032;; miR-181a-5p forward, 5&#x2032;-CGGCAACATTCAACGCTGT-3&#x2032; and reverse, 5&#x2032;-GTGCAGGGTCCGAGGTATTC-3&#x2032;; ROCK2 forward, 5&#x2032;-CTAGGCCGGGCGAAG-3&#x2032; and reverse, 5&#x2032;-TCCAGCTTCCTCTGACGAC-3&#x2032;; GAPDH forward, 5&#x2032;-GGTGCTGAGTATGTCGTGGAGTCTA-3&#x2032; and reverse, 5&#x2032;-TCTTGAGGGAGTTGTCATATTTCTC-3&#x2032;; U6 forward, 5&#x2032;-CTTCGGCAGCACATATAC-3&#x2032; and reverse, 5&#x2032;-GAACGCTTCACGAATTTGC-3&#x2032;. GAPDH and U6 were used as internal controls. The 2<sup>&#x2212;&#x0394;&#x0394;Cq</sup> method was used to normalize the fold change in expression (<xref rid="b16-or-0-0-8093" ref-type="bibr">16</xref>).</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Total protein was isolated from tissue and cells using RIPA lysis (cat. no. 28191; Norgen Biotek) was used to extract total protein. A BCA kit (cat. no. C-0018-30; Bioss) was used to determine the protein content. After denaturation, the proteins (5 &#x00B5;g) were separated by 10&#x0025; SDS-PAGE and transferred to PVDF membranes. A solution of 5&#x0025; skimmed milk was used to block the membranes at room temperature for 1 h. Then, the membranes were incubated with anti-caspase-3 (1:500 dilution; product code ab4051; Abcam), anti-cleaved caspase-3 (1:500 dilution; product code ab32042; Abcam), anti-ROCK2 (1:1,000 dilution; cat. no. orb251570; Biorbyt, Ltd.), anti-GAPDH (1:1,000 dilution; cat. no. G13-61M-100; SignalChem Biotech, Inc.) at 4&#x00B0;C overnight, followed by incubation with secondary antibodies IHC Select Streptavidin-HRP (1:1,000 dilution; cat. no. 20774; EMD Millipore) at room temperature for 2 h. The enhanced chemiluminescence kit (cat. no. orb90502; Biorbyt, Ltd.) was used to visualize the immunoreactive signals. GAPDH was used as an internal control. ImageJ 1.8.0 software (National Institutes of Health) was used to quantify the density of target bands.</p>
</sec>
<sec>
<title>Cell Counting Kit-8 (CCK-8)</title>
<p>CCK-8 (item no. R22305; Shanghai Yuanye Bio-Technology, Co. Ltd.) was used to examine cell proliferation. HCT116 cells and T84 cells (5,000 cells/well) /well were plated into a 96-well plate and then cultured in an incubator (37&#x00B0;C, 5&#x0025; CO<sub>2</sub>). After 48 h, 10 &#x00B5;l of CCK-8 was added into each well at 0, 24, 48, 72 and 96 h. Then, after 1 h, the optical density at 450 nm was measured by a microtiter plate reader.</p>
</sec>
<sec>
<title>Flow cytometry</title>
<p>Flow cytometry was used to examine the cell apoptosis rate. HCT116 cells and T84 cells (5,000 cells) were collected using trypsin and washed with PBS. Then, an Annexin V-FITC/PI apoptosis detection kit (cat. no. 556547; BD Biosciences) was used according to the manufacturer&#x0027;s instructions. The fluorescence intensity of the cells was quantified by flow cytometry (BD FACSCalibur&#x2122;). Flow cytometry analysis was performed using FlowJo10.0.0 (FlowJo, LLC).</p>
</sec>
<sec>
<title>Cell migration assay</title>
<p>A Transwell assay was used to evaluate HCT116 and T84 cell migration ability using Transwell chambers (8-&#x00B5;m pore size; cat. no. MCEP06H48; EMD Millipore). Cell suspensions (100 &#x00B5;l cell suspension/well) were prepared in serum-free medium and plated in the upper chamber, while the lower chamber was filled with medium containing 10&#x0025; FBS (cat. no. DXT-10099141, Gibco; Thermo Fisher Scientific, Inc.). The chamber was incubated for 24 h at 37&#x00B0;C. After 24 h, the cells in the upper chamber were removed with a swab, and the cells that migrated into the lower chamber were fixed in 75&#x0025; methanol (item no. JKLN042113; Shanghai Jingke technology Co., Ltd.) for 30 min and stained with 1&#x0025; crystal violet (item no. J12750; Duoxi) for 1 h at room temperature. The migrated cells were observed and imaged under a light microscope at a magnification of &#x00D7;40 in 5 randomly selected visual fields in each group.</p>
</sec>
<sec>
<title>Dual-luciferase reporter assay</title>
<p>The binding sites between circNSUN2 and miR-181a-5p and between miR-181a-5p and ROCK2 were predicted by starBase2.0 (<uri xlink:href="https://starbase.sysu.edu.cn/">http://starbase.sysu.edu.cn/</uri>) and TargetScan7.1 (<uri xlink:href="https://www.targetscan.org/vert_71/">http://www.targetscan.org/vert_71/</uri>). A dual-luciferase reporter assay was used to verify the relationship between circNSUN2 and miR-181a-5p and between miR-181a-5p and ROCK2. The circNSUN2 or ROCK2 region containing wild-type (WT) or mutant (MUT) binding sites of miR-181a-5p were cloned into pGL4.49 vector (cat. no. E4611; Promega Corporation). The 293T cells were plated and co-transfected with vectors by Lipofectamine 2000 according to the manufacturer&#x0027;s protocol. After 48 h, the luciferase activity was determined by a Dual-luciferase Reporter Assay kit (cat. no. K801-200, BioVision, Inc.). Firefly luciferase activity was normalized to <italic>Renilla</italic> luciferase activity.</p>
</sec>
<sec>
<title>In vivo tumor growth assay</title>
<p>An <italic>in vivo</italic> tumor growth assay was used to examine tumor growth. All animal experiments were approved by the Experimental Animal Ethics Committee of Kunming Medical University and adhered to international guidelines for proper animal care and maintenance. Nude mice (n=24; male; 3&#x2013;4 weeks old; weight 19&#x2013;25 g) purchased from the Animal Center of Kunming Medical University were randomly separated into four groups and housed in a pathogen-free facility (28&#x00B0;C; 55&#x0025; humidity; 12-h light/dark cycle with food and water <italic>ad libitum</italic>). Approximately 1&#x00D7;10<sup>6</sup> HCT116 and T84 cells with stable expression of si-circNSUN2 and NC were subcutaneously injected into BALB/C nude mice. Mice were under daily monitoring. The tumor volume was monitored at 4, 8, 12, 16, 20, 24, and 28 days using manual calipers after injection. Tumors were obtained at 4 weeks after injection. At the end of the experiment, six nude mice in each group were euthanized by anesthesia-mediated by overdose pentobarbital sodium via intravenous injection and tumors were harvested. The sacrifice of mice was confirmed by cessation of breathing and heartbeat which were monitored. The maximal tumor volume allowed in this experiment was 1.8 cm<sup>3</sup>. The tumor volume was measured according to the following equation: (width)<sup>2</sup>x(length/2).</p>
</sec>
<sec>
<title>TUNEL staining</title>
<p>TUNEL staining was used to evaluate tumor apoptosis. The tumors were removed from the mice, fixed in 4&#x0025; formaldehyde at room temperature for 24 h and then embedded in paraffin. Then, the tumors were sectioned into 4-&#x00B5;m sections and adhered to slides. A TUNEL kit (cat. no. 4500-0121-1; Merck KGaA) was used to stain the sections at 37&#x00B0;C for 30&#x2013;60 min according to the manufacturer&#x0027;s instructions. After washing the slides with PBS and air drying, the apoptotic cells were assessed in 10 randomly selected fields under a confocal microscope at a magnification of &#x00D7;40.</p>
</sec>
<sec>
<title>Statistical analyses</title>
<p>The data are presented as the mean &#x00B1; standard deviation (SD). Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc.). He statistical significance of differences between two groups was evaluated by paired Student&#x0027;s t-test and significant difference between more than two groups was evaluated with one-way ANOVA by Tukey&#x0027;s post hoc test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Expression of circNSUN2 in CRC tissues and cell lines</title>
</sec>
<sec>
<title>circRNAs have been revealed to be aberrantly expressed in various tumors (<xref rid="b17-or-0-0-8093" ref-type="bibr">17</xref>)</title>
<p>In the present study, the expression of circNSUN2 was examined in colorectal cancer tissues and cell lines by RT-qPCR. The results revealed that circNSUN2 was highly expressed in colorectal cancer tissues compared with adjacent tissues (<xref rid="f1-or-0-0-8093" ref-type="fig">Fig. 1A</xref>; P&#x003C;0.01). Moreover, the expression levels of circNSUN2 were higher in CRC cell lines, especially in HCT116 and T84 cells (<xref rid="f1-or-0-0-8093" ref-type="fig">Fig. 1B</xref>; P&#x003C;0.05 and P&#x003C;0.01) compared with NCM460 cells. Therefore, HCT116 and T84 cells were selected for the following experiments. Notably, the aforementioned results indicated that circNSUN2 was highly expressed in CRC tissues and cell lines.</p>
</sec>
<sec>
<title>circNSUN2 promotes proliferation, migration and inhibits apoptosis of CRC in vivo and in vitro</title>
<p>To determine the function of circNSUN2 in CRC, circNSUN2 was first knocked down in HCT116 and T84 cells by specific siRNA and the transfection efficiency was validated by RT-qPCR (<xref rid="f2-or-0-0-8093" ref-type="fig">Fig. 2A</xref>; P&#x003C;0.05). Functionally, CCK-8 assays and Transwell assays revealed that inhibition of circNSUN2 attenuated cell proliferation and migration, while flow cytometric assays and western blot assays indicated that inhibition of circNSUN2 promoted cell apoptosis (<xref rid="f2-or-0-0-8093" ref-type="fig">Fig. 2B-E</xref>; P&#x003C;0.05 and P&#x003C;0.01). Moreover, the <italic>in vivo</italic> tumor growth assay results revealed that knockdown of circNSUN2 inhibited tumor growth in terms of both volume and weight (<xref rid="f2-or-0-0-8093" ref-type="fig">Fig. 2F</xref>; P&#x003C;0.05). In addition, TUNEL staining results revealed that compared with the NC group, the apoptosis of tumor cells in si-circNSUN2 group increased (<xref rid="f2-or-0-0-8093" ref-type="fig">Fig. 2G</xref>). Hence, knockdown of circNSUN2 markedly inhibited the malignant biological behavior of CRC <italic>in vivo</italic> and <italic>in vitro</italic>.</p>
</sec>
<sec>
<title>Relationship between circNSUN2 and miR-181a-5p</title>
<p>Based on the results from the bioinformatics database starBase, miR-181a-5p was predicted to be a target gene of circNSUN2 (<xref rid="f3-or-0-0-8093" ref-type="fig">Fig. 3A</xref>). Dual-luciferase reporter assay results revealed that the luciferase activity of the circNSUN2 WT reporter was decreased in the miR-181a-5p mimics group, but the luciferase activity of the circNSUN2 MUT reporter was not significantly different from that of the NC group (<xref rid="f3-or-0-0-8093" ref-type="fig">Fig. 3B</xref>; P&#x003C;0.05). Moreover, RT-qPCR results revealed that the expression level of miR-181a-5p was increased in the si-circNSUN2 group of HCT116 and T84 cells (<xref rid="f3-or-0-0-8093" ref-type="fig">Fig. 3C</xref>; P&#x003C;0.05). In addition, RT-qPCR results revealed that the expression levels of miR-181a-5p in the CRC cell lines HCT116 and T84 were decreased compared with those in the normal colonic epithelial cell line NCM460 (<xref rid="f3-or-0-0-8093" ref-type="fig">Fig. 3D</xref>; P&#x003C;0.05). Therefore, circNSUN2 targeted miR-181a-5p and downregulated its expression in the CRC cell lines HCT116 and T84. In addition, miR-181a-5p was downregulated in CRC cell lines.</p>
</sec>
<sec>
<title>miR-181a-5p is involved in the development of CRC and dysregulated by circNSUN2</title>
<p>In order to determine the role of miR-181-5p in circNSUN2-mediated malignant biological behavior of CRC cells, miR-181a-5p mimics transfection was performed. The transfection efficiency was determined by RT-qPCR (<xref rid="f4-or-0-0-8093" ref-type="fig">Fig. 4A</xref>; P&#x003C;0.05). As revealed in <xref rid="f4-or-0-0-8093" ref-type="fig">Fig. 4B and C</xref>, miR-181a-5p overexpression resulted in decreased proliferation rates and migration abilities of HCT116 and T84 cells (P&#x003C;0.05). Moreover, forced miR-181a-5p expression increased the apoptotic rate of HCT116 and T84 cells (<xref rid="f4-or-0-0-8093" ref-type="fig">Fig. 4D and E</xref>; P&#x003C;0.05 and P&#x003C;0.01). In addition, rescue experiments were performed to validate the relationship between circNSUN2 and miR-181a-5p. Transfection of HCT116 and T84 cells with si-circNSUN2 had a significant influence on miR-181-5p overexpression-mediated malignant biological behavior (<xref rid="f4-or-0-0-8093" ref-type="fig">Fig. 4A-E</xref>). Overall, these results indicated that overexpression of miR-181-5p attenuated the effects of circNSUN2 inhibition on HCT116 and T84 cell behaviors.</p>
</sec>
<sec>
<title>miR-181-5p directly targets ROCK2</title>
<p>miRNAs function by modulating the expression of target genes (<xref rid="b18-or-0-0-8093" ref-type="bibr">18</xref>). According to bioinformatics analysis, ROCK2 was revealed as a target of miR-181a-5p (<xref rid="f5-or-0-0-8093" ref-type="fig">Fig. 5A</xref>). Moreover, dual-luciferase reporter assay results revealed that overexpression of miR-181a-5p decreased the luciferase activity of the ROCK2 WT reporter but had no effect on the ROCK2 MUT reporter (<xref rid="f5-or-0-0-8093" ref-type="fig">Fig. 5B</xref>; P&#x003C;0.05). Moreover, western blotting revealed that overexpression of miR-181a-5p downregulated the expression of ROCK2 in HCT116 and T84 cells (<xref rid="f5-or-0-0-8093" ref-type="fig">Fig. 5C</xref>; P&#x003C;0.05). Therefore, these results indicated that ROCK2 is a direct target of miR-181a-5p in CRC.</p>
</sec>
<sec>
<title>circNSUN2 upregulates ROCK2 expression through inhibition of miR-181a-5p</title>
<p>Since ROCK2 was validated as a direct target of miR-181a-5p, we next focused on ROCK2 to investigate its role in the malignant biological behavior of CRC cells. As revealed in <xref rid="f6-or-0-0-8093" ref-type="fig">Fig. 6A and B</xref>, the expression levels of ROCK2 in CRC cells and tissues were upregulated (P&#x003C;0.05). miR-181a-5p inhibitor transfection was determined by RT-qPCR (<xref rid="f6-or-0-0-8093" ref-type="fig">Fig. 6C</xref>; P&#x003C;0.01 and P&#x003C;0.001). Moreover, inhibition of circNSUN2 decreased the expression level of ROCK2 while miR-181a-5p knockdown increased the expression level of ROCK2 (<xref rid="f6-or-0-0-8093" ref-type="fig">Fig. 6D</xref>; P&#x003C;0.01 and P&#x003C;0.001), which indicated that circNSUN2 sponged miR-181a-5p to promote the expression of ROCK2. In order to determine the function of ROCK2 in CRC cell behaviors, HCT116 and T84 cells were transfected with siRNA targeting ROCK2 (<xref rid="f6-or-0-0-8093" ref-type="fig">Fig. 6E</xref>; P&#x003C;0.001). As revealed in <xref rid="f6-or-0-0-8093" ref-type="fig">Fig. 6F-I</xref>, ROCK2 downregulation led to decreased proliferation rates and migration abilities and increased apoptosis rates (P&#x003C;0.05, P&#x003C;0.01 and P&#x003C;0.001) in HCT116 and T84 cells. Thus, these results indicated that the circNSUN2/miR-181a-5p/ROCK2 axis played a critical role in CRC development.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In present study, it was demonstrated that circNSUN2 promoted the malignant biological behavior of CRC. The results further indicated that miR-181-5p and its target gene ROCK2 were involved in circNSUN2-mediated regulation of proliferation, apoptosis and migration of CRC cells. Thus, the present data indicated the circNSUN2/miR-181a-5p/ROCK2 axis as a critical regulator of malignant biological behavior in CRC.</p>
<p>CircRNAs are endogenous RNAs that are common and stable in eukaryotic cells (<xref rid="b19-or-0-0-8093" ref-type="bibr">19</xref>). Aberrant expression of circRNAs is identified as a crucial regulator in cancer progression (<xref rid="b9-or-0-0-8093" ref-type="bibr">9</xref>). For example, circRNA-100269 was downregulated in gastric cancer and suppressed tumor cell growth (<xref rid="b20-or-0-0-8093" ref-type="bibr">20</xref>), circPLEKHM3 functioned as a tumor suppressor in ovarian cancer cells (<xref rid="b21-or-0-0-8093" ref-type="bibr">21</xref>), circRNA 100146 was highly expressed in non-small cell lung cancer and functioned as an oncogene to promote cancer cell proliferation and invasion (<xref rid="b22-or-0-0-8093" ref-type="bibr">22</xref>). The role of circRNAs in CRC has been well studied. For example, decreased expression of hsa-circ-001988 may become a novel potential biomarker in the diagnosis of CRC (<xref rid="b23-or-0-0-8093" ref-type="bibr">23</xref>), circRNA0003906 expression was markedly downregulated in both CRC tissues and cell lines (<xref rid="b24-or-0-0-8093" ref-type="bibr">24</xref>), and downregulated circITGA7 was closely related to growth and metastasis of CRC (<xref rid="b25-or-0-0-8093" ref-type="bibr">25</xref>). It has been reported that circNSUN2 is positively related to CRC aggressiveness and can promote CRC metastasis progression (<xref rid="b26-or-0-0-8093" ref-type="bibr">26</xref>). However, the role of circNSUN2 in CRC cell proliferation, apoptosis and invasion warrants investigation. In the present study, it was determined that circNSUN2 was highly expressed in CRC tissues and cell lines, and knockdown of circNSUN2 inhibited the malignant biological behavior of CRC <italic>in vitro</italic> and suppressed tumor growth <italic>in vivo</italic>.</p>
<p>CircRNAs usually function as miRNA sponges to negatively regulate miRNA, and in turn modulate the expression of target genes. Liu <italic>et al</italic> (<xref rid="b27-or-0-0-8093" ref-type="bibr">27</xref>) revealed that hsa_circRNA_103809 promoted lung cancer progression via sponging miR-4302 and enhancing MYC expression. BCRC-3 activated p27 by targeting miR-182-5p and subsequently suppressed bladder cancer proliferation (<xref rid="b28-or-0-0-8093" ref-type="bibr">28</xref>). Su <italic>et al</italic> (<xref rid="b29-or-0-0-8093" ref-type="bibr">29</xref>) indicated that cTFRC promoted bladder cancer aggressiveness by targeting miR-107 and regulating TFRC expression. Bioinformatics analysis, in the present study, predicted that miR-181a-5p was a direct target of circNSUN2. Increasing evidence has revealed that miR-181a-5p plays a significant role in cancer development. miR-181a-5p-regulated MEG2 was revealed to function as a tumor suppressor in gastric cancer (<xref rid="b30-or-0-0-8093" ref-type="bibr">30</xref>). In ovarian cancer, miR-181a-5p was revealed to be associated with survival (<xref rid="b31-or-0-0-8093" ref-type="bibr">31</xref>). miR-181a-5p has also been revealed to be involved in chemoresistance (<xref rid="b32-or-0-0-8093" ref-type="bibr">32</xref>), cell proliferation (<xref rid="b33-or-0-0-8093" ref-type="bibr">33</xref>) and diagnosis (<xref rid="b13-or-0-0-8093" ref-type="bibr">13</xref>) of CRC. In addition, in the present study, it was observed that circNSUN2 directly targeted miR-181a-5p and miR-181a-5p participated in circNSUN2-mediated CRC cell proliferation, migration and apoptosis.</p>
<p>miR-181a-5p has been revealed to regulate malignant potential of cancer via different target genes, such as TGF&#x03B2;I (<xref rid="b34-or-0-0-8093" ref-type="bibr">34</xref>), CCAT1 (<xref rid="b35-or-0-0-8093" ref-type="bibr">35</xref>) and INPP5A (<xref rid="b36-or-0-0-8093" ref-type="bibr">36</xref>). In the present study, based on bioinformatics analysis, miR-181a-5p directly targeted ROCK2. The present study identified ROCK2 as a novel target gene of miR-181a-5p in CRC cells. ROCK2 has been reported to play a vital role in multiple cellular processes, such as proliferation (<xref rid="b37-or-0-0-8093" ref-type="bibr">37</xref>), apoptosis (<xref rid="b38-or-0-0-8093" ref-type="bibr">38</xref>), DNA repair (<xref rid="b39-or-0-0-8093" ref-type="bibr">39</xref>) and invasion (<xref rid="b40-or-0-0-8093" ref-type="bibr">40</xref>). A study indicated that ROCK2 contributed to the invasion and metastasis of CRC (<xref rid="b40-or-0-0-8093" ref-type="bibr">40</xref>). Furthermore, ROCK2 has been considered as a novel target for CRC therapy (<xref rid="b41-or-0-0-8093" ref-type="bibr">41</xref>). In this study, it was revealed that TFR1 overexpression restored the miR-107-mediated inhibitory effect on SW620 cells. In the present study, it was demonstrated that ROCK2 was overexpressed in CRC and associated with malignant biological behavior of CRC cells. Moreover, the expression of ROCK2 was modulated by circNSUN2 and miR-181a-5p. miR-181a-5p inhibition restored the circNSUN2-mediated inhibitory effect of ROCK2 expression.</p>
<p>However, the present study has some limitations. In particular, the methodological limitations should be noted. In order to confirm the biological function of circNSUN2 in CRC, the overexpression vector should be established and the effect of circNSUN2 on CRC cell proliferation and migration should be detected. In addition, there was an exploratory study limitation associated with circNSUN2. In a future study, transcriptome sequencing will be performed to further explore the potential role of circNSUN2 in CRC.</p>
<p>In summary, the present study revealed that circNSUN2 upregulated the expression of ROCK2 by sponging miR-181a-5p to facilitate proliferation, migration but inhibited the apoptosis of CRC. Thus, the study indicated that the circNSUN2/miR-181a-5p/ROCK2 axis may serve as a potential therapeutic target of CRC.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by the Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University [grant nos. 2019FE001(&#x2212;039)] and [2019FE001(&#x2212;302)]. It was also supported by the Leader Training Program in Medical Subjects of Health and Family Planning Commission of Yunnan Province (grant no. D-201657) and by the Department of Science and Technology of Yunnan Province (grant no. 201801YH00021).</p>
</sec>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>JC, SL and ZW contributed equally; they were major contributors in designing and analyzing this study. YS, CS, TZ and BX participated in the experiments, acquisition and analysis of data. YZ and XD made substantial contributions to the conception and design of the study. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>For the human tissues in this study, participation in the study and/or use of their tissue, informed consents were obtained from all participants. The study was approved by the Ethics Committee of First Affiliated Hospital of Kunming Medical University. All animal experiments were approved by the Experimental Animal Ethics Committee of Kunming Medical University and adhered to international guidelines for proper animal care and maintenance.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-or-0-0-8093"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><volume>70</volume><fpage>7</fpage><lpage>30</lpage><year>2020</year><pub-id pub-id-type="doi">10.3322/caac.21601</pub-id><pub-id pub-id-type="pmid">31912902</pub-id></element-citation></ref>
<ref id="b2-or-0-0-8093"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>BA</given-names></name><name><surname>Marshall</surname><given-names>JL</given-names></name><name><surname>Salem</surname><given-names>ME</given-names></name></person-group><article-title>The growing challenge of young adults with colorectal cancer</article-title><source>Oncology (Williston Park)</source><volume>31</volume><fpage>381</fpage><lpage>389</lpage><year>2017</year><pub-id pub-id-type="pmid">28516436</pub-id></element-citation></ref>
<ref id="b3-or-0-0-8093"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>ZP</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>HQ</given-names></name><name><surname>Ma</surname><given-names>FQ</given-names></name></person-group><article-title>ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro</article-title><source>Mol Med Rep</source><volume>14</volume><fpage>1714</fpage><lpage>1720</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/mmr.2016.5409</pub-id><pub-id pub-id-type="pmid">27314206</pub-id></element-citation></ref>
<ref id="b4-or-0-0-8093"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>AQ</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>A Six-LncRNA expression signature associated with prognosis of colorectal cancer patients</article-title><source>Cell Physiol Biochem</source><volume>50</volume><fpage>1882</fpage><lpage>1890</lpage><year>2018</year><pub-id pub-id-type="doi">10.1159/000494868</pub-id><pub-id pub-id-type="pmid">30396175</pub-id></element-citation></ref>
<ref id="b5-or-0-0-8093"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joranger</surname><given-names>P</given-names></name><name><surname>Nesbakken</surname><given-names>A</given-names></name><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Hoff</surname><given-names>G</given-names></name><name><surname>Oshaug</surname><given-names>A</given-names></name><name><surname>Aas</surname><given-names>E</given-names></name></person-group><article-title>Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: A model approach</article-title><source>Eur J Health Econ</source><volume>21</volume><fpage>321</fpage><lpage>334</lpage><year>2020</year><pub-id pub-id-type="doi">10.1007/s10198-019-01130-6</pub-id><pub-id pub-id-type="pmid">31707584</pub-id></element-citation></ref>
<ref id="b6-or-0-0-8093"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beermann</surname><given-names>J</given-names></name><name><surname>Piccoli</surname><given-names>MT</given-names></name><name><surname>Viereck</surname><given-names>J</given-names></name><name><surname>Thum</surname><given-names>T</given-names></name></person-group><article-title>Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches</article-title><source>Physiol Rev</source><volume>96</volume><fpage>1297</fpage><lpage>1325</lpage><year>2016</year><pub-id pub-id-type="doi">10.1152/physrev.00041.2015</pub-id><pub-id pub-id-type="pmid">27535639</pub-id></element-citation></ref>
<ref id="b7-or-0-0-8093"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnerio</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cheloni</surname><given-names>G</given-names></name><name><surname>Panella</surname><given-names>R</given-names></name><name><surname>Mae Katon</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>A</given-names></name><name><surname>Papa</surname><given-names>A</given-names></name><name><surname>Loretelli</surname><given-names>C</given-names></name><name><surname>Petri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intragenic antagonistic roles of protein and circRNA in tumorigenesis</article-title><source>Cell Res</source><volume>29</volume><fpage>628</fpage><lpage>640</lpage><year>2019</year><pub-id pub-id-type="doi">10.1038/s41422-019-0192-1</pub-id><pub-id pub-id-type="pmid">31209250</pub-id></element-citation></ref>
<ref id="b8-or-0-0-8093"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vo</surname><given-names>JN</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Engelke</surname><given-names>CG</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><etal/></person-group><article-title>The landscape of circular RNA in cancer</article-title><source>Cell</source><volume>176</volume><fpage>869</fpage><lpage>881.e13</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.021</pub-id><pub-id pub-id-type="pmid">30735636</pub-id></element-citation></ref>
<ref id="b9-or-0-0-8093"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name></person-group><article-title>A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling</article-title><source>Mol Cancer</source><volume>18</volume><fpage>47</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12943-019-1010-6</pub-id><pub-id pub-id-type="pmid">30925892</pub-id></element-citation></ref>
<ref id="b10-or-0-0-8093"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression</article-title><source>Mol Cancer</source><volume>18</volume><fpage>71</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12943-019-0969-3</pub-id><pub-id pub-id-type="pmid">30927924</pub-id></element-citation></ref>
<ref id="b11-or-0-0-8093"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Circ-ITGA7 sponges miR-3187-3p to upregulate ASXL1, suppressing colorectal cancer proliferation</article-title><source>Cancer Manag Res</source><volume>11</volume><fpage>6499</fpage><lpage>6509</lpage><year>2019</year><pub-id pub-id-type="doi">10.2147/CMAR.S203137</pub-id><pub-id pub-id-type="pmid">31372051</pub-id></element-citation></ref>
<ref id="b12-or-0-0-8093"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name></person-group><article-title>Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression</article-title><source>J Exp Clin Cancer Res</source><volume>38</volume><fpage>169</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s13046-019-1136-9</pub-id><pub-id pub-id-type="pmid">30999937</pub-id></element-citation></ref>
<ref id="b13-or-0-0-8093"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Shan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis</article-title><source>Gene</source><volume>687</volume><fpage>246</fpage><lpage>254</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.gene.2018.11.055</pub-id><pub-id pub-id-type="pmid">30458288</pub-id></element-citation></ref>
<ref id="b14-or-0-0-8093"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CC</given-names></name><name><surname>Wong</surname><given-names>CM</given-names></name><name><surname>Tung</surname><given-names>EK</given-names></name><name><surname>Man</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>IO</given-names></name></person-group><article-title>Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion</article-title><source>Hepatology</source><volume>49</volume><fpage>1583</fpage><lpage>1594</lpage><year>2009</year><pub-id pub-id-type="doi">10.1002/hep.22836</pub-id><pub-id pub-id-type="pmid">19205033</pub-id></element-citation></ref>
<ref id="b15-or-0-0-8093"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>R</given-names></name><name><surname>Paz</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Reichenbach</surname><given-names>DK</given-names></name><name><surname>Taylor</surname><given-names>PA</given-names></name><name><surname>Panoskaltsis-Mortari</surname><given-names>A</given-names></name><name><surname>Vulic</surname><given-names>A</given-names></name><name><surname>Luznik</surname><given-names>L</given-names></name><name><surname>MacDonald</surname><given-names>KK</given-names></name><name><surname>Hill</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism</article-title><source>Blood</source><volume>127</volume><fpage>2144</fpage><lpage>2154</lpage><year>2016</year><pub-id pub-id-type="doi">10.1182/blood-2015-10-678706</pub-id><pub-id pub-id-type="pmid">26983850</pub-id></element-citation></ref>
<ref id="b16-or-0-0-8093"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b17-or-0-0-8093"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group><article-title>Emerging roles of circRNA in formation and progression of cancer</article-title><source>J Cancer</source><volume>10</volume><fpage>5015</fpage><lpage>5021</lpage><year>2019</year><pub-id pub-id-type="doi">10.7150/jca.30828</pub-id><pub-id pub-id-type="pmid">31602252</pub-id></element-citation></ref>
<ref id="b18-or-0-0-8093"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Jeon</surname><given-names>HS</given-names></name><name><surname>Hong</surname><given-names>MJ</given-names></name><name><surname>Choi</surname><given-names>YY</given-names></name><name><surname>Kang</surname><given-names>HG</given-names></name><name><surname>Yoo</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Jeong</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><etal/></person-group><article-title>A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer</article-title><source>Ann Oncol</source><volume>26</volume><fpage>1142</fpage><lpage>1148</lpage><year>2015</year><pub-id pub-id-type="doi">10.1093/annonc/mdv100</pub-id><pub-id pub-id-type="pmid">25716425</pub-id></element-citation></ref>
<ref id="b19-or-0-0-8093"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Sorrentino</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Slevin</surname><given-names>MK</given-names></name><name><surname>Burd</surname><given-names>CE</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Marzluff</surname><given-names>WF</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name></person-group><article-title>Circular RNAs are abundant, conserved, and associated with ALU repeats</article-title><source>RNA</source><volume>19</volume><fpage>141</fpage><lpage>157</lpage><year>2013</year><pub-id pub-id-type="doi">10.1261/rna.035667.112</pub-id><pub-id pub-id-type="pmid">23249747</pub-id></element-citation></ref>
<ref id="b20-or-0-0-8093"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630</article-title><source>Aging (Albany NY)</source><volume>9</volume><fpage>1585</fpage><lpage>1594</lpage><year>2017</year><pub-id pub-id-type="doi">10.18632/aging.101254</pub-id><pub-id pub-id-type="pmid">28657541</pub-id></element-citation></ref>
<ref id="b21-or-0-0-8093"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer</article-title><source>Mol Cancer</source><volume>18</volume><fpage>144</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12943-019-1080-5</pub-id><pub-id pub-id-type="pmid">31623606</pub-id></element-citation></ref>
<ref id="b22-or-0-0-8093"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Nan</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer</article-title><source>Mol Cancer</source><volume>18</volume><fpage>13</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12943-019-0943-0</pub-id><pub-id pub-id-type="pmid">30665425</pub-id></element-citation></ref>
<ref id="b23-or-0-0-8093"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances</article-title><source>Int J Clin Exp Pathol</source><volume>8</volume><fpage>16020</fpage><lpage>16025</lpage><year>2015</year><pub-id pub-id-type="pmid">26884878</pub-id></element-citation></ref>
<ref id="b24-or-0-0-8093"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><article-title>The expression profile and clinical significance of circRNA0003906 in colorectal cancer</article-title><source>Onco Targets Ther</source><volume>10</volume><fpage>5187</fpage><lpage>5193</lpage><year>2017</year><pub-id pub-id-type="doi">10.2147/OTT.S147378</pub-id><pub-id pub-id-type="pmid">29123417</pub-id></element-citation></ref>
<ref id="b25-or-0-0-8093"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7</article-title><source>J Pathol</source><volume>246</volume><fpage>166</fpage><lpage>179</lpage><year>2018</year><pub-id pub-id-type="doi">10.1002/path.5125</pub-id><pub-id pub-id-type="pmid">29943828</pub-id></element-citation></ref>
<ref id="b26-or-0-0-8093"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>RX</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>LP</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><name><surname>Pan</surname><given-names>ZZ</given-names></name><name><surname>Ma</surname><given-names>XD</given-names></name><name><surname>Han</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Judde</surname><given-names>JG</given-names></name><name><surname>Deas</surname><given-names>O</given-names></name><etal/></person-group><article-title>N<sup>6</sup>-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis</article-title><source>Nat Commun</source><volume>10</volume><fpage>4695</fpage><year>2019</year><pub-id pub-id-type="doi">10.1038/s41467-019-12651-2</pub-id><pub-id pub-id-type="pmid">31619685</pub-id></element-citation></ref>
<ref id="b27-or-0-0-8093"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name></person-group><article-title>Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302</article-title><source>Biochem Biophys Res Commun</source><volume>500</volume><fpage>846</fpage><lpage>851</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.04.172</pub-id><pub-id pub-id-type="pmid">29698681</pub-id></element-citation></ref>
<ref id="b28-or-0-0-8093"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Tao</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name></person-group><article-title>Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis</article-title><source>Mol Cancer</source><volume>17</volume><fpage>144</fpage><year>2018</year><pub-id pub-id-type="doi">10.1186/s12943-018-0892-z</pub-id><pub-id pub-id-type="pmid">30285878</pub-id></element-citation></ref>
<ref id="b29-or-0-0-8093"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression</article-title><source>Mol Cancer</source><volume>18</volume><fpage>27</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s12943-019-0951-0</pub-id><pub-id pub-id-type="pmid">30782157</pub-id></element-citation></ref>
<ref id="b30-or-0-0-8093"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Fen</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name></person-group><article-title>MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells</article-title><source>Mol Cancer</source><volume>16</volume><fpage>133</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12943-017-0695-7</pub-id><pub-id pub-id-type="pmid">28747184</pub-id></element-citation></ref>
<ref id="b31-or-0-0-8093"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrillo</surname><given-names>M</given-names></name><name><surname>Zannoni</surname><given-names>GF</given-names></name><name><surname>Beltrame</surname><given-names>L</given-names></name><name><surname>Martinelli</surname><given-names>E</given-names></name><name><surname>DiFeo</surname><given-names>A</given-names></name><name><surname>Paracchini</surname><given-names>L</given-names></name><name><surname>Craparotta</surname><given-names>I</given-names></name><name><surname>Mannarino</surname><given-names>L</given-names></name><name><surname>Vizzielli</surname><given-names>G</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: A retrospective longitudinal analysis using matched tumor biopsies</article-title><source>Ann Oncol</source><volume>27</volume><fpage>625</fpage><lpage>634</lpage><year>2016</year><pub-id pub-id-type="doi">10.1093/annonc/mdw007</pub-id><pub-id pub-id-type="pmid">26782955</pub-id></element-citation></ref>
<ref id="b32-or-0-0-8093"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>JW</given-names></name><name><surname>Zhang</surname><given-names>BM</given-names></name><name><surname>Lv</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Gu</surname><given-names>XY</given-names></name><name><surname>Yu</surname><given-names>ZW</given-names></name><name><surname>Jia</surname><given-names>YH</given-names></name><name><surname>Bai</surname><given-names>XF</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/&#x03B2;-catenin signaling</article-title><source>Mol Cancer</source><volume>16</volume><fpage>9</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12943-017-0583-1</pub-id><pub-id pub-id-type="pmid">28086904</pub-id></element-citation></ref>
<ref id="b33-or-0-0-8093"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>SY</given-names></name><name><surname>Shan</surname><given-names>TD</given-names></name><name><surname>Pan</surname><given-names>XT</given-names></name><name><surname>Tian</surname><given-names>ZB</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Liu</surname><given-names>FG</given-names></name><name><surname>Sun</surname><given-names>XG</given-names></name><name><surname>Xue</surname><given-names>HG</given-names></name><name><surname>Li</surname><given-names>XH</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The lncRNA ZEB1-AS1 sponges miR-181a-5p to promote colorectal cancer cell proliferation by regulating Wnt/&#x03B2;-catenin signaling</article-title><source>Cell Cycle</source><volume>17</volume><fpage>1245</fpage><lpage>1254</lpage><year>2018</year><pub-id pub-id-type="doi">10.1080/15384101.2018.1471317</pub-id><pub-id pub-id-type="pmid">29886791</pub-id></element-citation></ref>
<ref id="b34-or-0-0-8093"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>G</given-names></name></person-group><article-title>Interference of the long noncoding RNA CDKN2B-AS1 upregulates miR-181a-5p/TGF&#x03B2;I axis to restrain the metastasis and promote apoptosis and senescence of cervical cancer cells</article-title><source>Cancer Med</source><volume>8</volume><fpage>1721</fpage><lpage>1730</lpage><year>2019</year><pub-id pub-id-type="doi">10.1002/cam4.2040</pub-id><pub-id pub-id-type="pmid">30884187</pub-id></element-citation></ref>
<ref id="b35-or-0-0-8093"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression</article-title><source>Aging (Albany NY)</source><volume>12</volume><fpage>8301</fpage><lpage>8320</lpage><year>2020</year><pub-id pub-id-type="doi">10.18632/aging.103139</pub-id><pub-id pub-id-type="pmid">32380476</pub-id></element-citation></ref>
<ref id="b36-or-0-0-8093"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Lou</surname><given-names>G</given-names></name></person-group><article-title>miR-181a-5p promotes proliferation and invasion and inhibits apoptosis of cervical cancer cells via regulating inositol polyphosphate-5-phosphatase A (INPP5A)</article-title><source>Oncol Res</source><volume>26</volume><fpage>703</fpage><lpage>712</lpage><year>2018</year><pub-id pub-id-type="doi">10.3727/096504017X14982569377511</pub-id><pub-id pub-id-type="pmid">28653606</pub-id></element-citation></ref>
<ref id="b37-or-0-0-8093"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Ke</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion</article-title><source>Clin Exp Med</source><volume>17</volume><fpage>519</fpage><lpage>529</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s10238-016-0444-z</pub-id><pub-id pub-id-type="pmid">27921230</pub-id></element-citation></ref>
<ref id="b38-or-0-0-8093"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title>mi-R4435-2HG promotes proliferation and inhibits apoptosis of cancer cells in ovarian carcinoma by upregulating ROCK2</article-title><source>Oncol Lett</source><volume>19</volume><fpage>1305</fpage><lpage>1309</lpage><year>2020</year><pub-id pub-id-type="pmid">31966061</pub-id></element-citation></ref>
<ref id="b39-or-0-0-8093"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pranatharthi</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Udayashankar</surname><given-names>AH</given-names></name><name><surname>Bhavani</surname><given-names>C</given-names></name><name><surname>Suresh</surname><given-names>SB</given-names></name><name><surname>Krishna</surname><given-names>S</given-names></name><name><surname>Thatte</surname><given-names>J</given-names></name><name><surname>Srikantia</surname><given-names>N</given-names></name><name><surname>Ross</surname><given-names>CR</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name></person-group><article-title>RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer</article-title><source>J Exp Clin Cancer Res</source><volume>38</volume><fpage>392</fpage><year>2019</year><pub-id pub-id-type="doi">10.1186/s13046-019-1385-7</pub-id><pub-id pub-id-type="pmid">31488179</pub-id></element-citation></ref>
<ref id="b40-or-0-0-8093"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name></person-group><article-title>Rock2 stabilizes &#x03B2;-catenin to promote tumor invasion and metastasis in colorectal cancer</article-title><source>Biochem Biophys Res Commun</source><volume>467</volume><fpage>629</fpage><lpage>637</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.10.103</pub-id><pub-id pub-id-type="pmid">26505794</pub-id></element-citation></ref>
<ref id="b41-or-0-0-8093"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Tai</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway</article-title><source>J Exp Clin Cancer Res</source><volume>37</volume><fpage>27</fpage><year>2018</year><pub-id pub-id-type="doi">10.1186/s13046-018-0683-9</pub-id><pub-id pub-id-type="pmid">29439714</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-0-0-8093" position="float">
<label>Figure 1.</label>
<caption><p>Expression of circNSUN2 in CRC tissues and cell lines. (A) Expression of circNSUN2 in colorectal cancer tissues and adjacent tissues was assessed by RT-qPCR assay. &#x002A;&#x002A;P&#x003C;0.01 (obtained using a two-tailed unpaired Student&#x0027;s t-test). circNSUN2. (B) Expression levels of circNSUN2 in a normal colonic epithelial cell line (NCM460) and CRC cell lines (HCT116, DiFi, HROC18 and T84) were assessed by RT-qPCR assay. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 (calculated by one-way ANOVA with Tukey&#x0027;s post hoc test for multiple comparisons). Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). circNSUN2, circRNA NOP2/Sun domain family, member 2; CRC, colorectal cancer; RT-qPCR, reverse-transcription-quantitative PCR.</p></caption>
<graphic xlink:href="or-46-01-8093-g00.tif"/>
</fig>
<fig id="f2-or-0-0-8093" position="float">
<label>Figure 2.</label>
<caption><p>circNSUN2 promotes proliferation, migration and inhibits apoptosis of CRC <italic>in vivo</italic> and <italic>in vitro</italic>. (A) Expression of circNSUN2 in HCT116 and T84 cells was assessed by RT-qPCR assay. &#x002A;P&#x003C;0.05. (B) Proliferation of HCT116 and T84 cells was assessed by CCK-8 assay. &#x002A;P&#x003C;0.05. (C) Migration of HCT116 and T84 cells was measured by Transwell assay. &#x002A;P&#x003C;0.05. (D) Apoptosis of HCT116 and T84 cells was measured by flow cytometry. &#x002A;&#x002A;P&#x003C;0.01. (E) Apoptosis of HCT116 and T84 cells was assessed by western blotting. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01. (F) Representative images of tumors from the implanted mice are presented. The time course of changes in the tumor volume and tumor weight of the implanted mice. &#x002A;P&#x003C;0.05. (G) TUNEL staining of the tumors from the implanted mice. Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 obtained using two-tailed unpaired Student&#x0027;s t-test. circNSUN2, circRNA NOP2/Sun domain family, member 2; CRC, colorectal cancer; RT-qPCR, reverse-transcription-quantitative PCR; CCK-8, Cell Counting Kit-8; NC, negative control.</p></caption>
<graphic xlink:href="or-46-01-8093-g01.tif"/>
</fig>
<fig id="f3-or-0-0-8093" position="float">
<label>Figure 3.</label>
<caption><p>Relationship between circNSUN2 and miR-181a-5p. (A) The binding site of miR-181a-5p and circNSUN2 was predicted by starBase. (B) The interaction of circNSUN2 and miR-181a-5p was determined by dual-luciferase reporter assay. &#x002A;P&#x003C;0.05. (C) Expression of miR-181a-5p in HCT116 and T84 cells was assessed by RT-qPCR assay. &#x002A;P&#x003C;0.05. (D) Expression of miR-181a-5p in a normal colonic epithelial cell line (NCM460) and CRC cell lines (HCT116 and T84) was assessed by RT-qPCR assay. &#x002A;P&#x003C;0.05. Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). Statistical significance was calculated by one-way ANOVA with Tukey&#x0027;s post hoc test for multiple comparisons in D. &#x002A;P&#x003C;0.05 obtained using two-tailed unpaired Student&#x0027;s t-test. circNSUN2, circRNA NOP2/Sun domain family, member 2; miR-181a-5p, microRNA-181a-5p; RT-qPCR, reverse-transcription-quantitative PCR; CRC, colorectal cancer; WT, wild-type; MUT, mutant; NC, negative control; si-, small interfering.</p></caption>
<graphic xlink:href="or-46-01-8093-g02.tif"/>
</fig>
<fig id="f4-or-0-0-8093" position="float">
<label>Figure 4.</label>
<caption><p>miR-181a-5p is involved in the development of CRC and is dysregulated by circNSUN2. (A) Expression of miR-181a-5p in HCT116 and T84 cells was measured by RT-qPCR assay. &#x002A;P&#x003C;0.05. (B) Proliferation of HCT116 and T84 cells was measured by CCK-8 assay. &#x002A;P&#x003C;0.05. (C) Migration of HCT116 and T84 cells was assessed by Transwell assay. &#x002A;P&#x003C;0.05. (D) Apoptosis of HCT116 and T84 cells was assessed by flow cytometry. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01. (E) Apoptosis of HCT116 and T84 cells was measured by western blotting. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01. Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). Statistical significance was calculated by one-way ANOVA with Tukey&#x0027;s post hoc test for multiple comparisons in A-E. miR-181a-5p, microRNA-181a-5p; CRC, colorectal cancer; circNSUN2, circRNA NOP2/Sun domain family, member 2; RT-qPCR, reverse-transcription-quantitative PCR; CCK-8, Cell Counting Kit-8; NC, negative control.</p></caption>
<graphic xlink:href="or-46-01-8093-g03.tif"/>
</fig>
<fig id="f5-or-0-0-8093" position="float">
<label>Figure 5.</label>
<caption><p>Interaction between miR-181a-5p and ROCK2. (A) The binding site of miR-181a-5p and ROCK2 was predicted by starBase and TargetScan. (B) The interaction of ROCK2 and miR-181a-5p was determined by dual-luciferase reporter assay. &#x002A;P&#x003C;0.05. (C) Expression of ROCK2 in HCT116 and T84 cells was measured by western blotting. &#x002A;P&#x003C;0.05. Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). &#x002A;P&#x003C;0.05 obtained using two-tailed unpaired Student&#x0027;s t-test. miR-181a-5p, microRNA-181a-5p; ROCK2, Rho-associated coiled-coil-containing protein kinase 2; WT, wild-type; MUT, mutant; NC, negative control.</p></caption>
<graphic xlink:href="or-46-01-8093-g04.tif"/>
</fig>
<fig id="f6-or-0-0-8093" position="float">
<label>Figure 6.</label>
<caption><p>circNSUN2 upregulates ROCK2 expression through inhibition of miR-181a-5p. (A) Expression of ROCK2 in a normal colonic epithelial cell line (NCM460) and CRC cell lines (HCT116 and T84) was measured by western blotting. &#x002A;P&#x003C;0.05. (B) Expression of ROCK2 in CRC tissues was measured by western blotting. N, normal tissue; C, cancerous tissue. &#x002A;P&#x003C;0.05. (C) Expression of miR-181a-5p was detected by qPCR. &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001. (D) Expression of ROCK2 in transfected HCT116 and T84 cells was assessed by western blotting. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01. (E) Expression of ROCK2 in transfected HCT116 and T84 cells was assessed by western blotting. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. (F) Proliferation of HCT116 and T84 cells was measured by CCK-8 assay. &#x002A;P&#x003C;0.05. (G) Migration of HCT116 and T84 cells was assessed by Transwell assay. &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001. (H) Apoptosis of HCT116 and T84 cells was assessed by flow cytometry. &#x002A;&#x002A;P&#x003C;0.01. (I) Apoptosis of HCT116 and T84 cells was assessed by western blotting. &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01. Data are expressed as the mean &#x00B1; SD (n=3 biological replicates). Statistical significance was calculated by one-way ANOVA with Tukey&#x0027;s post hoc test for multiple comparisons in A and D. For all other parts, &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 were obtained using two-tailed unpaired Student&#x0027;s t-test. circNSUN2, circRNA NOP2/Sun domain family, member 2; ROCK2, Rho-associated coiled-coil-containing protein kinase 2; CRC, colorectal cancer; CCK-8, Cell Counting Kit-8; miR-181a-5p, microRNA-181a-5p; si-, small interfering; si-con, si-control.</p></caption>
<graphic xlink:href="or-46-01-8093-g05.tif"/>
</fig>
</floats-group>
</article>
